Navigation Links
A Drug With Efficacy Superior to That of Xenical at Inducing Weight Loss Would Earn a 40 Percent Patient Share in the Obesity Drug Market
Date:6/12/2008

Advantages in Efficacy and Delivery Will Make Qnexa the New Clinical Gold Standard Drug by 2011, According to a New Report from Decision Resources

WALTHAM, Mass., June 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug that is more effective than Roche's Xenical at inducing weight loss would earn a 40 percent patient share in the obesity drug market, according to surveyed primary care physicians. Although other efficacy measures-such as the effect on weight maintenance-are also important to prescribers, the biggest unmet need within this indication is a therapy that can consistently induce more than ten percent weight loss. The Food and Drug Administration currently requires that a drug elicit between five and ten percent weight loss to get approval.

The new report entitled Obesity: Current Pipeline Falls Short of Physicians' Expectations for Efficacy and Safety finds that Vivus's Qnexa will become Decision Resources' proprietary clinical gold standard by 2011 due to its competitive advantages in efficacy and delivery over the 2006 gold standard, Xenical. By 2016 however, Orexigen's Empatic will supersede Qnexa due to its advantage in safety. Both Empatic and Qnexa are fixed dose combinations of currently marketed central nervous system agents used for indications like epilepsy, alcohol dependence and depression.

"Phase II clinical trial data revealed that Qnexa caused a greater overall weight reduction compared with pooled data for Xenical after a 24-week treatment period," said Donny Wong, Ph.D., principal analyst at Decision Resources. "According to physicians we surveyed, Empatic's overall score for safety and tolerability is better, based on the perception that this combination agent is more conducive to longer-term treatment."

About the Report

Obesity: Current Pipeline Falls Short of Physicians' Expectations fo
'/>"/>

SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
5. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
6. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)...  Boston Scientific Corporation (NYSE: BSX ) ... quarter ended March 31, 2015, compared to the ... to $1.800 billion.  This represents 6 percent operational ... and flat revenue on a reported basis, all ... achieved adjusted earnings per share of $0.21 for ...
(Date:4/28/2015)... PARSIPPANY, N.J. and INDIANAPOLIS , ... who undergo an angioplasty procedure and receive a heart stent ... help prevent a heart attack, a blood clot in their ... survey conducted by Harris Poll found that 52 percent of ... missed taking or changed the way they take their prescribed ...
(Date:4/28/2015)... April 28, 2015  Shares of Celladon Corp. (NASDAQ: ... yesterday following the announcement of poor drug trial results of ... gene therapy agent, MYDICAR.  The selloff may be warranted ... company at bargain basement prices. An analyst ... overview, current pipeline, financial review, analyst summary, valuation, and ...
Breaking Medicine Technology:Boston Scientific Announces Results for First Quarter 2015 2Boston Scientific Announces Results for First Quarter 2015 3Boston Scientific Announces Results for First Quarter 2015 4Boston Scientific Announces Results for First Quarter 2015 5Boston Scientific Announces Results for First Quarter 2015 6Boston Scientific Announces Results for First Quarter 2015 7Boston Scientific Announces Results for First Quarter 2015 8Boston Scientific Announces Results for First Quarter 2015 9Boston Scientific Announces Results for First Quarter 2015 10Boston Scientific Announces Results for First Quarter 2015 11Boston Scientific Announces Results for First Quarter 2015 12Boston Scientific Announces Results for First Quarter 2015 13Boston Scientific Announces Results for First Quarter 2015 14Boston Scientific Announces Results for First Quarter 2015 15Boston Scientific Announces Results for First Quarter 2015 16Boston Scientific Announces Results for First Quarter 2015 17Boston Scientific Announces Results for First Quarter 2015 18Boston Scientific Announces Results for First Quarter 2015 19Boston Scientific Announces Results for First Quarter 2015 20Boston Scientific Announces Results for First Quarter 2015 21Boston Scientific Announces Results for First Quarter 2015 22Boston Scientific Announces Results for First Quarter 2015 23Boston Scientific Announces Results for First Quarter 2015 24Boston Scientific Announces Results for First Quarter 2015 25Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 2Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 3Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 4Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 5Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 6Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 7Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 8Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 9Examining what's Left after MYDICAR Drug Trial Ends In Failure; Celladon Corp. Analyst Report Issued by BrokerBank Securities, Inc. 2
... Knopp Neurosciences Inc. ("Knopp"),announced that the U.S. ... Development has granted orphan drug designation to ... (ALS). (Logo: http://www.newscom.com/cgi-bin/prnh/20070924/KNOPPLOGO ) ... studies to evaluate the safety,tolerability and pharmacokinetics ...
... on stringent endpoint of clinical ... PHILADELPHIA, Oct. 15 An analysis of data to,be ... Scientific Meeting found that Asacol, dosed at 2.4 g/day, ... active,ulcerative colitis (UC). The analysis was based on data ...
Cached Medicine Technology:Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS 2New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients 2New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients 3New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients 4
(Date:4/28/2015)... Vancouver, BC (PRWEB) April 28, 2015 ... published a blog stating that it is smarter to ... of a personal injury claim. The blog reasons that ... lawyer since these professional are well-versed with the law ... the client would be able to on their own. ...
(Date:4/28/2015)... City, Missouri (PRWEB) April 28, 2015 ... by the American Museum of Natural History, will open ... spring 2016, supported by sponsorship from Saint Luke’s Health ... New York City, Toronto, Granada and Milan, this one-of-a-kind ... about science and technology. , “Saint Luke’s and ...
(Date:4/28/2015)... Chicago, IL (PRWEB) April 28, 2015 ... enhance its research and healthcare services programs, the ... Orlando, Ph.D. Orlando comes to MDA from Fidelity ... oversaw funding of research projects in neurodegenerative diseases ... scientific conferences. Prior to her time at Fidelity, ...
(Date:4/28/2015)... Colorado (PRWEB) April 28, 2015 Colorado ... an updated version of his popular spine education website ... ASKSPINEDOC.COM developed by eMedical Media. This website has ... of the anatomy of the spine, causes of neck ... Dr. Corenman created this website and personally answers questions ...
(Date:4/28/2015)... OsteoRemedies®, LLC, Memphis, TN, offers the ... infected hip and knee arthroplasty. , ... pre-loaded spacer with Gentamicin Antibiotics, for consistent and ... Combined with a consistent process for polishing the ... for temporary use for up to 180 days. ...
Breaking Medicine News(10 mins):Health News:Vancouver Personal Injury Lawyers Recently Stated in Latest Blog That It Is Smarter To Call A Lawyer Before ICBC 2Health News:Saint Luke's Health System to sponsor Brain: The Inside Story exhibition at Museum at Prairiefire 2Health News:MDA Adds Neurological Disease Expert to Research Team 2Health News:MDA Adds Neurological Disease Expert to Research Team 3Health News:Colorado Spine Surgeon Donald Corenman, MD, DC Launches Updated Version of NECKANDBACK.COM and Popular Back Pain Forum ASKSPINEDOC.COM 2Health News:Colorado Spine Surgeon Donald Corenman, MD, DC Launches Updated Version of NECKANDBACK.COM and Popular Back Pain Forum ASKSPINEDOC.COM 3
... debilitating headaches , , THURSDAY, Feb. 12 (HealthDay News) -- Being ... and middle-aged adults, suggests a U.S. study that included 22,211 ... was distributed affected migraine risk. People ages 20 to 55 ... than those with smaller waistlines. , Migraine was reported by ...
... By The Bay, a regional resource for hospice ... end-of-life care at no charge to all healthcare ... starting in March. CEUs are available. The ongoing ... held in Larkspur. For the schedule of trainings, ...
... MINNEAPOLIS, Feb. 12 Biotel Inc.,(OTC Bulletin Board: BTEL) ... with net earnings of $289,000, or $0.10 per diluted ... of $206,000, or $0.07,per diluted share, on revenues of ... six months ended December 31, 2008, Biotel had net ...
... The Disabled American Veterans today applauds the introduction ... predictable funding for veterans health care and an ... budget process."The Veterans Health Care Budget Reform and ... efficient, transparent and accountable. These are three key ...
... the government,s vaccine program," says SafeMinds.WASHINGTON, Feb. 12 ... three families who argued that vaccination contributed to their ... on inadequate vaccine safety science available to the court. ... the defendant in "vaccine court" and is also responsible ...
... Arrow Group, a New York-based full-service strategic consulting ... Schweinitz has joined the company.As a member of ... be responsible for driving business growth by ensuring ... expanding Big Arrow,s offerings and expertise, especially in ...
Cached Medicine News:Health News:Belly Fat May Make Migraines More Likely 2Health News:Hospice By The Bay Offers Health Care Professionals Free Training in End-of-Life Care 2Health News:Hospice By The Bay Offers Health Care Professionals Free Training in End-of-Life Care 3Health News:Biotel Announces Profitable Second Quarter Ended December 31, 2008 2Health News:Veterans Health Care Funding Reform Bill Promises Transparency, Accountability 2Health News:Veterans Health Care Funding Reform Bill Promises Transparency, Accountability 3Health News:Federal Vaccine Court Rulings Against Autism Families Due to Government's Refusal to Fund Sound Science 2Health News:Big Arrow Group Expands Global Capabilities with Addition of Anne de Schweinitz 2
Pneumatic micro sagittal saw, 30k cpm, available with various hose connector styles....
... As part of our continued effort to standardize ... to introduce the new PowerPro® Electric II Handpiece ... single trigger handpiece, a dedicated oscillating saw, a ... to this system are features such as speed, ...
... Introducing the new large power ... function as both cordless AND electric ... Its the versatility the industry has ... the MicroAire name. Power ...
... Linvatec Advantage System is a full-function, ... electric handpieces for a wide range ... Bone Orthopedics, Small Bone Orthopedics, Orthopedic ... Neurosurgery, and Spine Surgery. Because it ...
Medicine Products: